| Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer T Reinert, TV Henriksen, E Christensen, S Sharma, R Salari, H Sethi, ... JAMA oncology 5 (8), 1124-1131, 2019 | 705 | 2019 |
| Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma E Christensen, K Birkenkamp-Demtröder, H Sethi, S Shchegrova, R Salari, ... Journal of Clinical Oncology 37 (18), 1547-1557, 2019 | 426 | 2019 |
| ctDNA guiding adjuvant immunotherapy in urothelial carcinoma T Powles, ZJ Assaf, N Davarpanah, R Banchereau, BE Szabados, ... Nature 595 (7867), 432-437, 2021 | 409 | 2021 |
| Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer D Kotani, E Oki, Y Nakamura, H Yukami, S Mishima, H Bando, H Shirasu, ... Nature medicine 29 (1), 127-134, 2023 | 198 | 2023 |
| Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of … TV Henriksen, N Tarazona, A Frydendahl, T Reinert, F Gimeno-Valiente, ... Clinical Cancer Research, 2021 | 149 | 2021 |
| Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL S Kadri, J Lee, C Fitzpatrick, N Galanina, M Sukhanova, G Venkataraman, ... Blood Advances 1 (12), 715-727, 2017 | 135 | 2017 |
| Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays S Kadri, BC Long, I Mujacic, CJ Zhen, MN Wurst, S Sharma, N McDonald, ... The Journal of Molecular Diagnostics 19 (1), 43-56, 2017 | 122 | 2017 |
| Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians S Sharma, M Das, A Kumar, V Marwaha, S Shankar, P Singh, P Raghu, ... Pharmacogenetics and genomics 19 (10), 823-828, 2009 | 97 | 2009 |
| Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases F Loupakis, S Sharma, M Derouazi, S Murgioni, P Biason, MD Rizzato, ... JCO Precision Oncology 5, 1166-1177, 2021 | 93 | 2021 |
| Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder B Szabados, M Kockx, ZJ Assaf, PJ van Dam, A Rodriguez-Vida, I Duran, ... European Urology 82 (2), 212-222, 2022 | 91 | 2022 |
| Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL S Sharma, N Galanina, A Guo, J Lee, S Kadri, C Van Slambrouck, B Long, ... Oncotarget 7 (42), 68833, 2016 | 90 | 2016 |
| Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors PM Kasi, G Fehringer, H Taniguchi, N Starling, Y Nakamura, D Kotani, ... JCO Precision Oncology 6, e2100181, 2022 | 68 | 2022 |
| Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE … M Kotaka, H Shirasu, J Watanabe, K Yamazaki, K Hirata, N Akazawa, ... Journal of Clinical Oncology 40 (4_suppl), 9-9, 2022 | 67 | 2022 |
| Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians S Sharma, M Das, A Kumar, V Marwaha, S Shankar, R Aneja, R Grover, ... Pharmacogenetics and genomics 18 (12), 1041-1049, 2008 | 67 | 2008 |
| Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations S Sharma, Z Jin, E Rosenzweig, S Rao, K Ko, TB Niewold Journal of autoimmunity 60, 51-58, 2015 | 66 | 2015 |
| B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy L Zhang, K Nomie, H Zhang, T Bell, L Pham, S Kadri, J Segal, S Li, ... Clinical Cancer Research 23 (15), 4212-4223, 2017 | 57 | 2017 |
| XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB M Ming, W Wu, B Xie, M Sukhanova, W Wang, S Kadri, S Sharma, J Lee, ... Molecular Cancer Therapeutics 17 (12), 2564-2574, 2018 | 41 | 2018 |
| Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients. TV Henriksen, N Tarazona, T Reinert, JA Carbonell-Asins, D Renner, ... Journal of Clinical Oncology 39 (3_suppl), 11-11, 2021 | 33 | 2021 |
| Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers BM Huffman, VN Aushev, GL Budde, J Chao, F Dayyani, D Hanna, ... JCO Precision Oncology 6, e2200420, 2022 | 31 | 2022 |
| Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a UK multicenter prospective … G Anandappa, N Starling, R Begum, A Bryant, S Sharma, D Renner, ... Journal of Clinical Oncology 39 (3_suppl), 102-102, 2021 | 31 | 2021 |